20 articles
A phase III trial of 408 men finds metformin does not delay prostate cancer progression during active surveillance — and may worsen outcomes in obese patients.
Six-month trial examines whether metformin treatment can improve telomere length and longevity gene expression in prediabetic individuals.
A 1.6-million-person cohort study finds metformin neither prevents AMD development nor slows progression to advanced disease stages.
A comprehensive review reveals metformin's polypharmacological mechanisms—from AMPK activation to gut microbiome remodeling—that may delay aging and enhance cancer immunotherapy.
Six-month trial finds diabetes drug metformin significantly reduces knee pain compared to placebo in people with osteoarthritis and excess weight.
A major review challenges the evidence behind metformin as a longevity drug, exposing methodological flaws in landmark studies.
A massive 860,000-patient multinational study finds metformin users face significantly lower delirium and mortality risk than those on DPP-4 inhibitors.
Research reveals how the diabetes drug metformin may extend lifespan and healthspan through multiple molecular pathways.
A 2025 narrative review examines metformin's benefits, risks, and sex-specific efficacy for prediabetic women navigating the menopausal transition.
Peter Attia dissects the null results of the MET-PREVENT trial and what they reveal about the hard science of testing aging interventions.
A sweeping 2025 review traces metformin from its 1922 synthesis to its emerging roles in cancer, aging, and longevity.
A landmark RCT of 5,047 type 2 diabetics finds GLP-1 agonists linked to fewer hospitalizations than other second-line therapies.
New review maps metformin's complex pathways beyond diabetes, showing how it targets cancer and aging through AMPK, mTOR, and mitochondrial mechanisms.
Large randomized trial finds metformin doesn't slow placental aging, challenging its potential as anti-aging therapy during pregnancy.
A landmark Nature study shows metformin can suppress the clonal advantage of DNMT3A-mutant blood stem cells, potentially preventing leukemia progression.
ATX-304 raised resting metabolic rate 8%, slashed triglycerides, and reduced liver fat in an 8-week Phase 1b trial for prediabetes.
A large real-world study finds GLP-1 drugs semaglutide and tirzepatide dramatically reduce heart failure hospitalization and death in HFpEF patients.
A phase 2 trial finds tesamorelin reduces abdominal obesity in virally suppressed HIV patients but shows no significant cognitive improvement.
Combining metformin and berberine outperforms either drug alone in reversing NAFLD by powerfully activating the AMPK–SREBP1–FASN lipid-regulation axis.
A 2025 review reveals how metformin's AMPK activation and mitochondrial effects may slow aging beyond its diabetes role.
